论文部分内容阅读
目的探讨IDA-FLAG方案治疗复发难治性急性白血病的临床疗效。方法将本院2008年5月至2009年1月收治的40例复发难治性急性白血病患者随机分为观察组(20例)和对照组(20例),对照组采用FLAG方案治疗,观察组采用IDA-FLAG方案治疗。比较分析两组的治疗情况。结果观察组缓解率为90%,对照组缓解率为60%,两组间比较,有显著性差异(P<0.05)。两组不良反应发生率及半年内复发率无显著性差异(P>0.05)。结论IDA-FLAG方案治疗复发难治性急性白血病有较好的效果,且安全可靠,值得推广应用。
Objective To investigate the clinical efficacy of IDA-FLAG regimen in the treatment of recurrent refractory acute leukemia. Methods Forty patients with relapsed and refractory acute leukemia admitted in our hospital from May 2008 to January 2009 were randomly divided into observation group (20 cases) and control group (20 cases). The control group was treated with FLAG. The observation group Treatment with IDA-FLAG regimen. Comparative analysis of the two groups of treatment. Results The remission rate was 90% in the observation group and 60% in the control group. There was significant difference between the two groups (P <0.05). There was no significant difference in the incidence of adverse reactions and relapse within six months (P> 0.05). Conclusion IDA-FLAG regimen has a good effect in relapse-refractory acute leukemia and is safe and reliable, which is worthy of promotion.